DE60137969D1 - Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält - Google Patents

Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält

Info

Publication number
DE60137969D1
DE60137969D1 DE60137969T DE60137969T DE60137969D1 DE 60137969 D1 DE60137969 D1 DE 60137969D1 DE 60137969 T DE60137969 T DE 60137969T DE 60137969 T DE60137969 T DE 60137969T DE 60137969 D1 DE60137969 D1 DE 60137969D1
Authority
DE
Germany
Prior art keywords
type
pseudomonas exotoxin
chimeric protein
protein containing
containing nontoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60137969T
Other languages
English (en)
Inventor
David Fitzgerald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60137969D1 publication Critical patent/DE60137969D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60137969T 2000-12-21 2001-12-20 Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält Expired - Lifetime DE60137969D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25787700P 2000-12-21 2000-12-21
PCT/US2001/049143 WO2002060935A2 (en) 2000-12-21 2001-12-20 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences

Publications (1)

Publication Number Publication Date
DE60137969D1 true DE60137969D1 (de) 2009-04-23

Family

ID=22978159

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137969T Expired - Lifetime DE60137969D1 (de) 2000-12-21 2001-12-20 Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält

Country Status (9)

Country Link
US (2) US7314625B2 (de)
EP (1) EP1379550B1 (de)
JP (2) JP2004528018A (de)
AT (1) ATE425180T1 (de)
CA (1) CA2432731A1 (de)
DE (1) DE60137969D1 (de)
DK (1) DK1379550T3 (de)
ES (1) ES2322240T3 (de)
WO (1) WO2002060935A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295971C (en) * 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
JP2003512441A (ja) 1999-10-22 2003-04-02 アメリカ合衆国 極性上皮細胞層を横断するタンパク質の送達
GB0212666D0 (en) 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
AU2005294436A1 (en) * 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
AU2005296064A1 (en) * 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
US20090155297A1 (en) * 2004-10-04 2009-06-18 Trinity Biosystems, Inc. Methods and Compositions for Inducing an Immune Response Against Multiple Antigens
CA2609038A1 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
EP1919494A4 (de) 2005-07-22 2011-11-09 Univ Colorado Regents Nichttoxischer biofolien-hemmer
CA2631952A1 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
US20070148131A1 (en) * 2005-12-05 2007-06-28 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
US20090305978A1 (en) * 2006-03-16 2009-12-10 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
US20100189776A1 (en) 2007-03-16 2010-07-29 Cancer Research Technology Ltd Anti-androgen peptides and uses thereof in cancer therapy
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
WO2011009624A1 (en) * 2009-07-22 2011-01-27 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
US8961984B2 (en) 2009-10-08 2015-02-24 Arch Biophysics, Inc. Surface-coated structures and methods
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2012101235A1 (en) * 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
EP4082558B1 (de) 2018-03-08 2023-08-23 Applied Molecular Transport Inc. Von toxinen abgeleitete konstrukte zur oralen verabreichung
CN113347997A (zh) 2018-11-07 2021-09-03 应用分子运输公司 用于经口递送异源有效载荷的Cholix衍生的携带体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735800A (en) * 1983-09-09 1988-04-05 Molecular Genetics, Inc. Vaccines against rift valley fever virus
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5082927A (en) 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
CA1340530C (en) * 1989-04-28 1999-05-04 Kok Kheong Lee Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
WO1991009871A1 (en) 1989-12-22 1991-07-11 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
DE69131449T2 (de) 1990-05-11 1999-11-25 Us Health Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
US5328984A (en) 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
AU3416693A (en) * 1991-12-18 1993-07-19 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University, The Antigenic preparations that stimulate production of antibodies which bind to the pili of type IV piliated bacteria
WO1993025690A1 (en) 1992-06-18 1993-12-23 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant pseudomonas exotoxin with increased activity
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
AU701302B2 (en) 1994-05-13 1999-01-21 Merck Patent Gesellschaft Mit Beschrankter Haftung Improvements in or relating to peptide delivery
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
WO1996013599A1 (en) 1994-11-01 1996-05-09 Winfried Wels Nucleic acid transfer system
DE69629580D1 (de) 1995-10-13 2003-09-25 Us Gov Health & Human Serv Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment
WO1998020135A2 (en) 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
US6086900A (en) 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
ATE340863T1 (de) 1997-07-11 2006-10-15 Us Gov Health & Human Serv Pseudomonas exotoxin a-ähnliche chimerische immunogene zum auslösen einer sekretorischen iga- vermittelten immunantwort
EP1082342A2 (de) 1998-05-06 2001-03-14 The Governors Of The University Of Alberta Pseudomonas aeruginosa impfstoff

Also Published As

Publication number Publication date
US7314625B2 (en) 2008-01-01
WO2002060935A8 (en) 2004-01-15
DK1379550T3 (da) 2009-07-06
JP2004528018A (ja) 2004-09-16
WO2002060935A3 (en) 2003-11-20
JP2008237227A (ja) 2008-10-09
WO2002060935A2 (en) 2002-08-08
CA2432731A1 (en) 2002-08-08
US20040071731A1 (en) 2004-04-15
EP1379550B1 (de) 2009-03-11
ATE425180T1 (de) 2009-03-15
US20070003578A1 (en) 2007-01-04
EP1379550A2 (de) 2004-01-14
ES2322240T3 (es) 2009-06-18

Similar Documents

Publication Publication Date Title
DE60137969D1 (de) Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
ATE466952T1 (de) Poly-zinkfinger-proteine mit verbesserten linkern
AU9063801A (en) Methods and compositions for diseases associated with amyloidosis
ATE366309T1 (de) Caspasen-aktivatoren
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
MXPA03011393A (es) Composicion para tenido de fibras queratinicas que comprende colorante diazoico dicationico particular.
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
HRP20010036B1 (en) Neurotrophic growth factor
RU2001104349A (ru) Композиции и способы для терапии и диагностики рака предстательной железы
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
DK1037916T3 (da) Erythrovirus og dets anvendelser
DE60139959D1 (de) Nukleinsäureadjuvantien
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
DE69938130D1 (de) Neue peptide
AU2487602A (en) Isolated luciferases and the use thereof
EA199900893A1 (ru) Бактериальные плазмиды
PE20399A1 (es) Muteina ob
TR200003608T2 (tr) Moraxella Catarrhalis'e ait BASB027 proteinleri ve genleri.
WO2002024864A3 (en) Antisense modulation of syntaxin 4 interacting protein expression
NO20014720D0 (no) In vivo fargeforbindelser og fremgangsmåter for anvendelse for identifisering av dysplastisk vev
KR970700770A (ko) Htra-프로모터를 사용하여 독성이 약화된 박테리아내에서 이종 단백질을 발현시키는 방법(expression of heterologous proteins in attenuated bacteria using the htra-promoters)
ITTO20001016A0 (it) Composizione per sigillatura.
ITMI20000894A0 (it) Dispositivo per la chiusura di un capo di abbigliamento o simile, ad elevata praticita' di impiego.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition